SCHEMBL5835671

SCHEMBL5835671

COc1cc(C)c(S(=O)(=O)Nc2ccc(C)c(O[C@@H]3CCN(C)C3)c2)cc1OC

nearest known ligand 0.67

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 10/20 0.67
HTR6 P50406 1/20 0.48
MCHR1 Q99705 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
RXFP1 Q9HBX9 1/20 0.44
HSD17B2 P37059 1/20 0.43
BRD4 O60885 1/20 0.43
BRD1 O95696 1/20 0.43
BRPF1 P55201 1/20 0.43
ALDH1A1 P00352 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
THRB P10828 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5835676 1.00 UTS2R (0.67) UTS2RHTR6MCHR1MEN1KMT2A
SCHEMBL5835709 0.91 UTS2R (0.81) UTS2RHTR6MCHR1
SCHEMBL5835523 0.91 UTS2R (0.81) UTS2RHTR6MCHR1MEN1KMT2A
SCHEMBL5834843 0.91 UTS2R (0.72) UTS2RHTR6MCHR1MEN1KMT2A
SCHEMBL5835527 0.91 UTS2R (0.81) UTS2RHTR6MCHR1MEN1KMT2A
SCHEMBL5834848 0.91 UTS2R (0.72) UTS2RHTR6MCHR1MEN1KMT2A
SCHEMBL5835716 0.91 UTS2R (0.81) UTS2RHTR6MCHR1
SCHEMBL5836216 0.91 UTS2R (0.81) UTS2RHTR6MCHR1
SCHEMBL5835427 0.87 LMNA (0.59) UTS2RMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL5835421 0.87 LMNA (0.59) UTS2RMEN1KMT2ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7026349-B2 Sulfonamides SMITHKLINE BEECHAM CORPORATION (US) 2006-04-11 US claimed
EP-1385507-A4 SULFONAMIDES SMITHKLINE BEECHAM CORP (US) 2005-11-23 EP claimed
US-20040152906-A1 Sulfonamides SHELL OIL COMPANY 2004-08-05 US claimed
EP-1385507-A1 SULFONAMIDES SmithKline Beecham Corporation (US) 2004-02-04 EP claimed
WO-2002089792-A1 SULFONAMIDES SMITHKLINE BEECHAM CORPORATION (US) 2002-11-14 WO claimed
US-7026349-B2 Sulfonamides SMITHKLINE BEECHAM CORPORATION (US) 2006-04-11 US disclosed
EP-1385507-A4 SULFONAMIDES SMITHKLINE BEECHAM CORP (US) 2005-11-23 EP disclosed
US-20040152906-A1 Sulfonamides SHELL OIL COMPANY 2004-08-05 US disclosed
EP-1385507-A1 SULFONAMIDES SmithKline Beecham Corporation (US) 2004-02-04 EP disclosed
WO-2002089792-A1 SULFONAMIDES SMITHKLINE BEECHAM CORPORATION (US) 2002-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152906-A1 Sulfonamides UTS2R, PRSS2, STS UTS2R 1/4885HTR6 2239/4885MCHR1 3777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.